Diagnosis and Management of Infantile Hemangioma

More documents

Recommendations

Info

40. Akyuz C, Yaris N, Kutluk MT, et al. Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Pediatr Hematol Oncol 2001 Jan-Feb;18(1):47-55. PMID: 11205840. 41. Chang CJ, Kelly KM, Nelson JS. Cryogen spray cooling and pulsed dye laser treatment of cutaneous hemangiomas. Ann Plast Surg 2001 Jun;46(6):577-83. PMID: 11405354. 42. Raulin C, Greve B. Retrospective clinical comparison of hemangioma treatment by flashlamp-pumped (585 nm) and frequency-doubled Nd:YAG (532 nm) lasers. Lasers Surg Med 2001;28(1):40-3. PMID: 11430441. 43. Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg 1997 Apr;99(5):1301-8. PMID: 9105356. 44. Achauer BM, Vander Kam VM. Capillary hemangioma (strawberry mark) of infancy: comparison of argon and Nd:YAG laser treatment. Plast Reconstr Surg 1989 Jul;84(1):60-9; discussion 70. PMID: 2734405. 45. Chen ZG, Zheng JW, Yuan ML, et al. A novel topical nano-propranolol for treatment of infantile hemangiomas. Nanomedicine 2015 Mar 16PMID: 25791814. 46. Chen W, Liu S, Yang C, et al. Clinical efficacy of the 595 nm pulsed dye laser in the treatment of childhood superficial hemangioma - analysis of 10-year application in Chinese patients. J Dermatolog Treat 2015 Feb;26(1):54-8. PMID: 23697537. 47. Raphael MF, Breugem CC, Vlasveld FA, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study. J Am Acad Dermatol 2015 Mar;72(3):465-72. PMID: 25592625. 48. Xu DP, Cao RY, Xue L, et al. Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. J Oral Maxillofac Surg 2015 Mar;73(3):430-6. PMID: 25544304. 49. Andersen IG, Rechnitzer C, Charabi B. Effectiveness of propanolol for treatment of infantile haemangioma. Dan Med J 2014 Feb;61(2):A4776. PMID: 24495884. 50. Chai Q, Chen WL, Huang ZQ, et al. Preliminary experiences in treating infantile hemangioma with propranolol. Ann Plast Surg 2014 Feb;72(2):169-72. PMID: 21629056. 51. Chen W, Yang C, Liu S, et al. Curative effect study of pulsed dye laser in the treatment of 43 patients with hand infantile hemangioma. Eur J Dermatol 2014 Jan-Feb;24(1):76-9. PMID: 24413474. 52. Chu DH, Castelo-Soccio L, Wan J, et al. Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study). Clin Pediatr (Phila) 2014 Oct;53(11):1084-90. PMID: 24849505. 53. Couto JA, Greene AK. Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. J Plast Reconstr Aesthet Surg 2014 Nov;67(11):1469-74. PMID: 25104131. 54. El Ezzi O, Hohlfeld J, de Buys Roessingh A. Propranolol in infantile haemangioma: simplifying pretreatment monitoring. Swiss Med Wkly 2014;144:w13943. PMID: 24610228. 55. Giachetti A, Garcia-Monaco R, Sojo M, et al. Long-term treatment with oral propranolol reduces relapses of infantile hemangiomas. Pediatr Dermatol 2014 Jan-Feb;31(1):14-20. PMID: 24283619. F-19
56. Hassan BA, Shreef KS. Propranolol in treatment of huge and complicated infantile hemangiomas in egyptian children. Dermatol Res Pract 2014;2014(541810)PMID: 2014377871. 57. Jian D, Chen X, Babajee K, et al. Adverse effects of propranolol treatment for infantile hemangiomas in China. J Dermatolog Treat 2014 Oct;25(5):388-90. PMID: 23216314. 58. Kaune KM, Lauerer P, Kietz S, et al. Combination therapy of infantile hemangiomas with pulsed dye laser and Nd:YAG laser is effective and safe. J Dtsch Dermatol Ges 2014 Jun;12(6):473-8. PMID: 24825388. 59. Ke Y, Hao R, He Y, et al. The value of color Doppler imaging and intralesional steroid injection in pediatric orbital capillary hemangioma. J Chin Med Assoc 2014 May;77(5):258-64. PMID: 24694673. 60. Kwon SH, Choi JW, Byun SY, et al. Effect of early long-pulse pulsed dye laser treatment in infantile hemangiomas. Dermatol Surg 2014 Apr;40(4):405-11. PMID: 24460784. 61. Lynch M, Lenane P, O'Donnell BF. Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients. Clin Exp Dermatol 2014 Mar;39(2):142-5. PMID: 24289272. 62. Martinez Roca C, Rodriguez Ruiz M, Vilaboa Pedrosa C, et al. Oral propranolol in the treatment of infantile hemangioma: A case series of 50 infants. European Journal of Pediatric Dermatology 2014 April-June;24(2):86-90. 63. May JE, Liew SH. A new treatment pathway for propranolol use in infantile haemangiomas. J Plast Reconstr Aesthet Surg 2014 Mar;67(3):e91-2. PMID: 24268691. 64. Muzaffar F, Shah GN. Propranolol for the treatment of infantile hemangioma: Our experience at The Children's Hospital, Lahore. Journal of Pakistan Association of Dermatologists 2014;24(4):312-8. 65. Park YW, Yeom KB, Choi JW, et al. Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience. J Dermatolog Treat 2014 Oct;25(5):391-5. PMID: 23273264. 66. Sagi L, Zvulunov A, Lapidoth M, et al. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. Dermatology 2014;228(2):136-44. PMID: 24556822. 67. Schneider M, Cremer HJ, Ruef P. A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. Acta Paediatr 2014 Sep;103(9):977-83. PMID: 24837972. 68. Schneider M, Reimer A, Cremer H, et al. Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas. World J Pediatr 2014 Nov;10(4):313-7. PMID: 25515804. 69. Solman L, Murabit A, Gnarra M, et al. Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. Arch Dis Child 2014 Dec;99(12):1132-6. PMID: 25123404. 70. Su W, Ke Y, Xue J. Beneficial effects of early treatment of infantile hemangiomas with a long-pulse Alexandrite laser. Lasers Surg Med 2014 Mar;46(3):173-9. PMID: 24391080. 71. Szychta P, Stewart K, Anderson W. Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg 2014 Apr;133(4):852-62. PMID: 24352207. F-20
Page 1 and 2:
Comparative Effectiveness Review Nu
Page 3 and 4:
This report is based on research co
Page 5 and 6:
Acknowledgments The authors gratefu
Page 7 and 8:
Peer Reviewers Prior to publication
Page 9 and 10:
BCI; moderate SOE for effects of pr
Page 11 and 12:
Overview of the Literature ........
Page 13 and 14:
Executive Summary Introduction Infa
Page 15 and 16:
for contextual questions as few eff
Page 17 and 18:
Figure B. Analytic framework for KQ
Page 19 and 20:
Table A. Inclusion criteria (contin
Page 21 and 22:
precision (precise, imprecise), and
Page 23 and 24:
Figure D. Estimates of expected IH
Page 25 and 26:
majority of studies to date have in
Page 27 and 28:
effectiveness outcomes. The evidenc
Page 29 and 30:
changes. We considered the strength
Page 31 and 32:
Table C. Summary of evidence in stu
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Table D. Summary of evidence in stu
Page 39 and 40:
Applicability We set inclusion crit
Page 41 and 42:
quantitative meta-analyses. Researc
Page 43 and 44:
surgically. Lesion characteristics
Page 45 and 46:
References 1. Wassef M, Blei F, Ada
Page 47 and 48:
39. Yu L, Li S, Su B, et al. Treatm
Page 49 and 50:
modalities. The questions of imagin
Page 51 and 52:
KQ2. Among newborns, infants, and c
Page 53 and 54:
of data, and compiling evidence. We
Page 55 and 56:
We only included studies published
Page 57 and 58:
a standardized form (Appendix B) th
Page 59 and 60:
Determining Quality Ratings • We
Page 61 and 62:
Results We present results for Cont
Page 63 and 64:
defects, urogenital anomalies, ulce
Page 65 and 66:
Results of Literature Searches for
Page 67 and 68:
Table 3. Characteristics of include
Page 69 and 70:
scans, had a sensitivity of 20 perc
Page 71 and 72:
of the model fit to all studies, bu
Page 73 and 74:
Detailed Analysis Effectiveness of
Page 75 and 76:
Table 6. Key resolution outcomes in
Page 77 and 78:
with prednisolone included endocrin
Page 79 and 80:
children in 8 studies), skin atroph
Page 81 and 82:
hypopigmentation, impaired wound he
Page 83 and 84:
fair quality for effectiveness outc
Page 85 and 86:
studies of nadolol and atenolol. No
Page 87 and 88:
Table 10. Key resolution outcomes i
Page 89 and 90:
old. 100 Thirty percent of children
Page 91 and 92:
Table 11. Resolution outcomes in st
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Table 15. Key outcomes in studies c
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Table 22. Harms/adverse effects in
Page 109 and 110:
Table 24. Adverse effects in case s
Page 111 and 112:
Table 24. Adverse effects in case s
Page 113 and 114:
• In two RCTs reporting level of
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Nd:YAG Laser With Cooling Compared
Page 121 and 122:
Page 123 and 124:
long term follow information was av
Page 125 and 126:
Discussion State of the Literature
Page 127 and 128:
Table 34. Strength of evidence for
Page 129 and 130:
Page 131 and 132:
Effectiveness and Harms of Beta-Blo
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
older children. One comparative stu
Page 151 and 152:
case series reporting on rarer pres
Page 153 and 154:
agents is critical, especially as u
Page 155 and 156:
References 1. Wassef M, Blei F, Ada
Page 157 and 158:
39. Chen TS, Eichenfield LF, Friedl
Page 159 and 160:
80. Mai HM, Zheng JW, Wang YA, et a
Page 161 and 162:
119. Sharma LK, Dalal SS. Corticost
Page 163 and 164:
162. Snir M, Reich U, Siegel R, et
Page 165 and 166:
198. Chen ZG, Zheng JW, Yuan ML, et
Page 167 and 168:
237. Healy G, McGill T, Friedman EM
Page 169 and 170:
Abbreviations and Acronyms Used in
Page 171 and 172:
Appendix A. Search Strategies Searc
Page 173 and 174:
Searches for Comparative Effectiven
Page 175 and 176:
Appendix B. Screening and Quality A
Page 177 and 178:
Harms Risk of Bias Assessment Form
Page 179 and 180:
QUADAS Diagnostic Accuracy Rating T
Page 181 and 182:
Infantile Hemangioma CER: Risk of B
Page 183 and 184:
20. Grundfest-Broniatowski S, Carey
Page 185 and 186:
65. Dachman AH, Lichtenstein JE, Fr
Page 187 and 188:
111. Yoshida T, Kuratomi K, Mitsuma
Page 189 and 190:
160. Newman SL, Goodwin CD. Colonic
Page 191 and 192:
204. Crockett DM, Healy GB, McGill
Page 193 and 194:
253. Wright GL, Smith RJ, Katz CD,
Page 195 and 196:
301. Paley D, Jackson RW. Synovial
Page 197 and 198:
346. Dombrowski MP, Budev H, Wolfe
Page 199 and 200:
390. Stringel G. Giant hemangioma:
Page 201 and 202:
436. Liu HC, Chang MH, Lue HC, et a
Page 203 and 204:
480. Casale AJ, Menashe DS. Massive
Page 205 and 206:
526. Taylor RS, Joseph DB, Kohaut E
Page 207 and 208:
571. Goldstein MH. The elastic flap
Page 209 and 210:
614. Salloum E, Flamant F, Caillaud
Page 211 and 212:
659. Fellows KE, Hoffer FA, Markowi
Page 213 and 214:
706. Weatherford DA, Abrams RS, Wal
Page 215 and 216:
749. Keleti D, Flickinger JC, Hobso
Page 217 and 218:
793. Van Campenhout I, Patriquin H.
Page 219 and 220:
836. Goldman MP, Fitzpatrick RE, Ru
Page 221 and 222:
880. Schulman SR, Jones BR, Slotnic
Page 223 and 224:
924. Egawa H, Berquist W, Garcia-Ke
Page 225 and 226:
968. Thompson DN, Taylor WF, Haywar
Page 227 and 228:
1013. Gregg CM, Wiatrak BJ, Koopman
Page 229 and 230:
1056. Rozylo TK, Krupski W, Galkows
Page 231 and 232:
1099. Fremont S, Kanny G, Bieber S,
Page 233 and 234:
1142. Sreeram N, Miller P, John P.
Page 235 and 236:
1185. Enjolras O, Wassef M, Mazoyer
Page 237 and 238:
1228. Paley MR, Farrant P, Kane P,
Page 239 and 240:
1271. Burrows PE, Robertson RL, Mul
Page 241 and 242:
1312. Lezama-del Valle P, Gerald WL
Page 243 and 244:
1352. Altunay IK, Gokdemir G, Koken
Page 245 and 246:
1394. Kiristioglu I, Kilic N, Gurpi
Page 247 and 248:
1437. Yoshida D, Sugisaki Y, Shimur
Page 249 and 250:
1480. Kreusel KM, Bechrakis NE, Hei
Page 251 and 252:
1523. Wilken JJ, Meier FA, Kornstei
Page 253 and 254:
1568. Garmendia G, Miranda N, Borro
Page 255 and 256:
1610. Park EA, Seo JW, Lee SW, et a
Page 257 and 258:
1652. Chatrath P, Black M, Jani P,
Page 259 and 260:
1694. Hopf M, Hopf JUG, Rohde E, et
Page 261 and 262:
1737. Rozylo-Kalinowska I, Brodzisz
Page 263 and 264:
1782. Coras B, Hohenleutner U, Land
Page 265 and 266:
1826. McQueen CT, Cullen RD. Endosc
Page 267 and 268:
1866. Tsao MN, Schwartz ML, Bernste
Page 269 and 270:
1909. Denier C, Labauge P, Brunerea
Page 271 and 272:
1950. Mounayer C, Benndorf G, Bisdo
Page 273 and 274:
1992. Woo SJ, Kim CJ, Yu YS. Cavern
Page 275 and 276:
2036. Ersoy S, Mancini AJ. Hemifaci
Page 277 and 278:
2077. Kronenberg A, Blei F, Ceisler
Page 279 and 280:
2117. Sabharwal GK, Strouse PJ. Pos
Page 281 and 282:
2159. Cannady SB, Kahn TA, Trabouls
Page 283 and 284:
2200. Karikari IO, Selznick LA, Cum
Page 285 and 286:
2241. Pienaar C, Graham R, Geldenhu
Page 287 and 288:
2283. Wananukul S, Voramethkul W, N
Page 289 and 290:
2327. Czernik A, Bystryn JC. Does i
Page 291 and 292:
2368. Kamida T, Takeda Y, Fujiki M,
Page 293 and 294:
2410. Rodgers B, Zeim S, Crawford B
Page 295 and 296:
2453. Zolkipli Z, Aylett S, Rankin
Page 297 and 298:
2495. Egberts F, Mentzel T, Leuschn
Page 299 and 300:
2537. Kutluhan A, Bozdemir K, Ugras
Page 301 and 302:
2580. Saetti R, Silvestrini M, Cutr
Page 303 and 304:
2620. Yun TJ, Na DG, Kwon BJ, et al
Page 305 and 306:
2661. Demirci H, Shields CL, Eagle
Page 307 and 308:
2700. Iriz A, Durmaz E, Akmansu SH,
Page 309 and 310:
2744. Ooi KG, Wenderoth JD, Francis
Page 311 and 312:
2786. Tyzio R, Khalilov I, Represa
Page 313 and 314:
2827. Bayliss SJ, Berk DR, Van Hare
Page 315 and 316:
2869. Fernandez-Pineda I, Lopez-Gut
Page 317 and 318:
2910. Kazim SF, Bhatti, Enam SA. In
Page 319 and 320:
2953. Nonogaki S, Campos HGA, Butug
Page 321 and 322:
2995. Storch CH, Hoeger PH. Propran
Page 323 and 324:
3038. Al Dhaybi R, Superstein R, Mi
Page 325 and 326:
3080. del Pozo J, Lopez-Gutierrez J
Page 327 and 328:
3120. Guye E, Chollet-Rivier M, Sch
Page 329 and 330:
3159. Kolokythas A, Al-Ghamian H, M
Page 331 and 332:
3201. Nale P. Propranolol treatment
Page 333 and 334:
3243. Soltani AM, Reinisch JF. Algo
Page 335 and 336:
3286. . Derm Dx. Clinical Advisor.
Page 337 and 338:
3326. Chang YT, Lin JY, Lee JY, et
Page 339 and 340:
3367. Gross BC, Janus JR, Orvidas L
Page 341 and 342:
3407. Kupeli S. Use of propranolol
Page 343 and 344:
3448. Raches D, Hiscock M, Chapiesk
Page 345 and 346:
3490. Traivaree C, Lumkul R, Torcha
Page 347 and 348: 3532. Ammerman RT, Putnam FW, Altay
Page 349 and 350: 3573. Chou S, Subramanian V, Lau HM
Page 351 and 352: 3614. Hyland RM, Komlosi K, Alleman
Page 353 and 354: 3655. Masetti R, Colecchia A, Ronde
Page 355 and 356: 3693. Parikh SR, Darrow DH, Grimmer
Page 357 and 358: 3732. Stiles JM, Amaya C, Rains S,
Page 359 and 360: 3772. Zou HX, Jia J, Zhang WF, et a
Page 361 and 362: 3813. Deng X, Wang K, Wu L, et al.
Page 363 and 364: 3851. Khorsand K, Backus S, Sidbury
Page 365 and 366: 3890. Phillips RJ, Lokmic Z, Crock
Page 367 and 368: 3930. Weil AG, Bhatia S. Resection
Page 369 and 370: 3969. Ravenscroft J. Management of
Page 371 and 372: where ΦΦ(xx) is the cumulative di
Page 373 and 374: Figure D-1. Estimates of expected I
Page 375 and 376: Figure D-3. Posterior SUCRA estimat
Page 377 and 378: Figure D-5. Network diagram of comp
Page 379 and 380: Appendix E. Study Design Classifica
Page 381 and 382: Author, Year Hogeling 2011 10 Alloc
Page 383 and 384: Author, Year Representativeness of
Page 385 and 386: Author, Year Were the harms predefi
Page 397: 25. Qiu Y, Ma G, Yang J, et al. Imi
Page 401 and 402: 88. Chakkittakandiyil A, Phillips R
Page 403 and 404: 120. Pandey A, Gangopadhyay AN, Gop
Page 405 and 406: Appendix G. Applicability Tables Ta
Page 407 and 408: Appendix H. Harms Reported in Packa
Page 409 and 410: o Acquired (autoimmune) hemolytic a
Page 411 and 412: o Ankylosing spondylitis o Dermatom
Page 413 and 414: H-7 • Increased dosage of rapidly
Page 415 and 416: Elocon® (mometason e furoate) 11 T
Page 417 and 418: Timoptic® (timolol maleate) 15 Tim
Page 419 and 420: Harms Data for Medications Included
Page 421 and 422: Table H-3: Adverse Events from Flo-
Page 423 and 424: (
Page 425 and 426: thromboembolism, thrombophlebitis,
Page 427 and 428: grades): 103 (48%), erosion/ulcerat
Page 429 and 430: acute myocardial infarction: 3 (Rat
Page 431 and 432: Discontinuations Patients utilizing
Page 433 and 434: ocular irritation including blephar
show all

Diagnosis and Management of Infantile Hemangioma

Create successful ePaper yourself

Delete template?

Save as template?